Ngashi Ngongo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ngashi Ngongo has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Adelar Lofungola
Institut National de Santé Publique (INSP), Kinshasa P.O. Box 3088, Democratic Republic of the Congo
2 shared publications - Adrienne Amuri-Aziza
Institut National de Recherche Biomédicale
2 shared publications - Aine O'Toole
Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
2 shared publications - Alemayehu Duga
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
2 shared publications - Andrew Rambaut
Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
2 shared publications - Anne W. Rimoin
Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
2 shared publications
Latest Publications
- Open Access
Mpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025
Clade I mpox virus (MPXV) is endemic in the Democratic Republic of the Congo (DRC). Recent studies have described the changing epidemiology of mpox in the country, which has been mainly characterized by the emergence of new MPXV lineages, Clade Ib/sh2023 and Ia/sh2024, associated with sustained human-to-human transmission. Both Clade Ib/sh2023 and Ia/sh2024 are co-circulating in Kinshasa, the capital city of the DRC. Here, we report the first two cases of Clade IIb/sh2017 identified in Kinshasa, DRC, imported from West Africa and locally transmitted. Clinical specimens were collected and tested by PCR. We performed whole genome sequencing using a tiled-amplicon sequencing approach with Clade IIb MPXV-specific primers. The phylogenetic tree shows that Kinshasa Clade IIb MPXV is assigned to Clade IIb/sh2017 within the newly designated lineage G.1, as identified in January 2025 in Sierra-Leone.
Open AccessMpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025
Clade I mpox virus (MPXV) is endemic in the Democratic Republic of the Congo (DRC). Recent studies have described the changing epidemiology of mpox in the country, which has been mainly characterized by the emergence of new MPXV lineages, Clade Ib/sh2023 and Ia/sh2024, associated with sustained human-to-human transmission. Both Clade Ib/sh2023 and Ia/sh2024 are co-circulating in Kinshasa, the capital city of the DRC. Here, we report the first two cases of Clade IIb/sh2017 identified in Kinshasa, DRC, imported from West Africa and locally transmitted. Clinical specimens were collected and tested by PCR. We performed whole genome sequencing using a tiled-amplicon sequencing approach with Clade IIb MPXV-specific primers. The phylogenetic tree shows that Kinshasa Clade IIb MPXV is assigned to Clade IIb/sh2017 within the newly designated lineage G.1, as identified in January 2025 in Sierra-Leone.
- Open Access
- 25 November 2025
- Published by MDPI AG in Preprints.org
Mpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025
Mpox virus lineages associated with sustained human-to-human transmission, Clade Ib/sh2023 and Ia/sh2024, are co-circulating in Kinshasa, Democratic Republic of the Congo (DRC). We report the first two Clade IIb/sh2017 cases identified in DRC, imported from West Africa and locally transmitted, with phylogenetic linkage to the ongoing outbreak in Sierra Leone.
- 25 November 2025
- Published by MDPI AG in Preprints.org
Open AccessMpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025
Mpox virus lineages associated with sustained human-to-human transmission, Clade Ib/sh2023 and Ia/sh2024, are co-circulating in Kinshasa, Democratic Republic of the Congo (DRC). We report the first two Clade IIb/sh2017 cases identified in DRC, imported from West Africa and locally transmitted, with phylogenetic linkage to the ongoing outbreak in Sierra Leone.
- 7 November 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10516) , 2215-2216
Africa leads, multilateral health organisations support
- 7 November 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10516) , 2215-2216
Africa leads, multilateral health organisations support
- Open Access
Strengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products
The World Health Organization (WHO) Global Benchmarking Tool (GBT) classifies regulatory systems into four maturity levels, with Maturity Level 3 (ML3) signifying a stable and effective regulatory environment. As of January 2025, eight African nations—Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe—have attained ML3 status, marking a significant milestone in the continent’s regulatory landscape. Achieving ML3 confers critical benefits, including reducing substandard and falsified medicines, which enhances public health safety and fosters trust in healthcare systems. This progress encourages local manufacturing, diminishing reliance on imported medicines and promoting economic development. Furthermore, ML3 NRAs are better equipped to address public health emergencies, enabling swift approvals for vaccines and therapeutics while upholding safety standards. Nonetheless, challenges persist, including fragmented regulatory systems, the prevalence of counterfeit medicines, and limited resources. Overcoming these hurdles necessitates enhanced organizational capacity, investments in training, and the promotion of collaboration among NRAs. There is an urgent call for greater political commitment and resource allocation to strengthen regulatory systems across Africa. Achieving and maintaining ML3 status is essential for enhancing medicine regulation, supporting local manufacturing, and improving public health outcomes across the continent. While progress has been made, sustained efforts are crucial to tackling existing challenges and harnessing the full potential of advanced regulatory frameworks.
Open AccessStrengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products
The World Health Organization (WHO) Global Benchmarking Tool (GBT) classifies regulatory systems into four maturity levels, with Maturity Level 3 (ML3) signifying a stable and effective regulatory environment. As of January 2025, eight African nations—Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe—have attained ML3 status, marking a significant milestone in the continent’s regulatory landscape. Achieving ML3 confers critical benefits, including reducing substandard and falsified medicines, which enhances public health safety and fosters trust in healthcare systems. This progress encourages local manufacturing, diminishing reliance on imported medicines and promoting economic development. Furthermore, ML3 NRAs are better equipped to address public health emergencies, enabling swift approvals for vaccines and therapeutics while upholding safety standards. Nonetheless, challenges persist, including fragmented regulatory systems, the prevalence of counterfeit medicines, and limited resources. Overcoming these hurdles necessitates enhanced organizational capacity, investments in training, and the promotion of collaboration among NRAs. There is an urgent call for greater political commitment and resource allocation to strengthen regulatory systems across Africa. Achieving and maintaining ML3 status is essential for enhancing medicine regulation, supporting local manufacturing, and improving public health outcomes across the continent. While progress has been made, sustained efforts are crucial to tackling existing challenges and harnessing the full potential of advanced regulatory frameworks.
- Open Access
- 9 October 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (10) , e015445
Malaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa
- 9 October 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (10) , e015445
Open AccessMalaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa